What Researchers Did
Researchers reviewed current evidence on emergent management and evolving treatment strategies for central retinal artery occlusion (CRAO) from observational studies, meta-analyses, and early randomized trials.
What They Found
Conservative interventions for CRAO showed no benefit and could be harmful, while intravenous thrombolysis with t-PA within 4.5 hours of symptom onset offered the strongest evidence for visual recovery. Although tenecteplase has pharmacologic advantages, it did not show clinical superiority over alteplase, and "eye stroke" protocols improved diagnostic efficiency.
What This Means for Canadian Patients
Canadian patients experiencing sudden vision loss, a symptom of CRAO, should seek immediate emergency medical attention, as timely diagnosis and treatment are crucial. If diagnosed with CRAO, intravenous thrombolysis within 4.5 hours of symptom onset offers the best chance for visual recovery, similar to acute stroke management.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or patients.
Study Limitations
The review highlights that effective treatment for CRAO is limited by delayed presentation, restricted therapeutic options, and a lack of sufficient randomized prospective trials.